PharmaTelevision - BayBio: Impact of US Presidential Elections on Biotech

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: BayBio: Impact of US Presidential Elections on Biotech

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this exclusive interview - filmed at the JP Morgan conference in San Francisco - Fintan Walton and Matt Gardner, President and CEO of BayBio, look back on 2007, beginning with Matt Gardner’s assessment of the biotech industry for the past year. Matt mentions the benchmarks that are used to quantify the state of the industry - which includes the status of the product pipelines of biotech companies. The interview moves on to discuss the key issues facing the biotech industry in light of the run-up to the 2008 US presidential elections. Matt talks about the major issues that one needs to be aware of with regard to the individual presidential candidates. These include their views on healthcare and on patent reform, and Matt says why he thinks the outcome of the patent reform debate is the most sensitive issue. The interview progresses towards examining the decline in venture funding of early-stage and seed companies - and how this may result in a future company ‘gap’. Personalised medicine, and its potential for eventually lowering the cost of healthcare is discussed. The interview concludes with Matt’s optimistic outlook for the industry.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Matt Gardner's assessment of the biotech industry for the past year.

Fintan Walton:

Welcome to PharmaVentures Business Review brought to you by PharmaTelevision the world's first on demand pharmaceutical television channel. We are here in San Francisco recording a series of interviews at the annual JP Morgan Conference. This conference was originally run by the famous Hambrecht and Quist Bank and is one of the oldest events in biotechnology. Today thousands to send from around the US but also from around the world into San Francisco to do financial deals and recently it's also become an important partnering event. I hope you'll enjoy the series of interviews we've done from some of the key companies attending this conference. Hello and welcome to PharmaVentures Business Review here in San Francisco. On this show I've Matt Gardner, who is President and CEO of BayBio the local organization for biotechnology companies here in the Bay area, welcome to the show Matt Gardner.

Matt Gardner:

Thanks Fintan, it's great to be with you again.

Fintan Walton:

Yes, well you said again because last year you were here and we were talking about what's gonna happen in 2007 so for you and your organization and your members has 2007 been a good year or bad year?

Matt Gardner:

That's been a fantastic year there was a couple of primary bench marks we use to take a look at that one is the state of the pipeline and the second might be the state of investment in the industry on a whole and both are at relative highs and in venture investment we see an all time high other than the year 2000 so in every sense it was a bang up year.

Fintan Walton:

You are about to launch your impact report which you do every year which looks at what's happened in 2007 where you see things going in 2008 and you talk about your pipeline, the pipeline being those companies that are based here in the BayBio area which is basically North California the Northern California?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Matt Gardner

CEO

Matt Gardner is President and CEO of BayBio . Mr. Matt Gardner oversees the company's activities in advocacy, industry advancement, membership benefits and communications. He has contributed content to a broad range of publications, from biotechnology articles in Manufacturing Today and Helix International magazines, to white papers on enterprise development and innovation policy. Mr. Matt Gardner previously held the position of Director of the Maryland Bioscience Alliance, in Rockville, Maryland. There, he was responsible for serving the Mid-Atlantic bioscience community. Before working for the Bioscience Alliance, he was the North American Director of Business Development for the Government of Queensland, Australia, which included responsibility for biotechnology initiatives. While serving Queensland, he founded and chaired of the Queensland-United States Bioscience Business Council. He was a member of the founding Global Board of Advisors for the Patent and License Exchange and was a charter member of the LA Morning Rotary Club serving downtown Los Angeles, California. Matt earned his Bachelor of Arts in Political Science and his Master of Arts in History, both from the University of San Diego.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

BayBio

BayBio is Northern California's life sciences association, and supports the regional bioscience community through advocacy, enterprise support and the enhancement of research collaboration. BayBio members include organizations engaged in, or supportive of, research, development and commercialization of life sciences technologies.